跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BLEXTEN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BLEXTEN
Authorized
STANDARD
BLEXTEN
aralez pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
b43dcd7b89267105
Company
aralez pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
b43dcd7b89267105
Drug Approval Canada Name
BLEXTEN
Product Name
BLEXTEN
Status
Marketed
Status Date
2022-02-10
Original Market Date
2022-02-10
Din
02519038
Drug Class
Human
Dosage Form
Tablet (Orally Disintegrating)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
04:08.00
Atc Original
R06AX29 BILASTINE
Atc Name
r 06 ax 29
Aig Number
0158051003
Company Name
aralez pharmaceuticals canada inc
Company Address
6733 Mississauga Rd, Suite 800, Mississauga, Ontario, Canada, L5N 6J5
Active Ingredients
BILASTINE
10 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
b43dcd7b89267105
Type
Standard
Back to Health Canada Approvals